Core Insights - The Boao Lecheng International Medical Tourism Pilot Zone held a conference on August 30, where 13 leading domestic biopharmaceutical companies signed agreements, with a total investment expected to exceed 3 billion yuan [1][2] - The collaboration aims to leverage the technological advantages of these companies along with the policy benefits of Hainan Free Trade Port to promote the application of new technologies, products, and solutions in the pilot zone [1] - The initiative seeks to establish a comprehensive biopharmaceutical industry cluster that integrates innovation research and development, pilot transformation, large-scale production, and clinical application [1] Group 1 - The Lecheng Pilot Zone is recognized as the only "medical special zone" in China and plays a crucial role in the construction of Hainan Free Trade Port [2] - The zone has developed a full-chain service system covering the rapid introduction of international innovative drugs and medical devices, clinical application, registration approval, and manufacturing [2] - It has been at the forefront of clinical transformation applications for new biomedical technologies such as cell therapy and gene editing, having approved 11 cutting-edge medical technology projects [2] Group 2 - The conference included presentations on the practical exploration and development opportunities of biomedical new technologies in the Lecheng Pilot Zone [1] - There was also an interpretation of Hainan Province's policies to further support the high-quality development of the biopharmaceutical industry [1] - The event highlighted the promotion of regional headquarters, research and development centers, and production bases to enhance the industry’s capabilities [1]